TrialClinical and translational science2021

Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.

Ravi Shankar P Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.